Browse our 650+ Publications
Latest Publications
Hyper-CVADand Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Kantarjian H, et al.
Am J Hematol
January 2025
Authors and Affiliates
Hagop Kantarjian | Nicholas J. Short | Nitin Jain | Fadi G. Haddad | Tapan Kadia | Musa Yilmaz |
Alessandra Ferrajoli | Koji Sasaki | Yesid Alvarado | Naveen Pemmaraju | Jayastu Senapati | Rebecca Garris |
Farhad Ravandi | Elias Jabbour
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
Nadeem O, et al.
Nature Communications
January 2025
Authors and Affiliates
Omar Nadeem1,2,8 , Michelle P. Aranha 1,2,3,8, Robert Redd 4,
Michael Timonian 1,2,3, Sophie Magidson 1, Elizabeth D. Lightbody1,2,3,
Jean-Baptiste Alberge 1,2,3, Luca Bertamini1,2,3, Ankit K. Dutta1,2,3,
Habib El-Khoury1,2,3, Mark Bustoros 1,5, Jacob P. Laubach1, Giada Bianchi6,
Elizabeth O’Donnell1, TingWu3, Junko Tsuji3, Kenneth C. Anderson 1,
Gad Getz2,3,7, Lorenzo Trippa4, Paul G. Richardson1,
Romanos Sklavenitis-Pistofidis1,2,3 & Irene M. Ghobrial 1,2,3
1Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 2Harvard
Medical School, Boston,MA,USA. 3Broad Institute ofMIT andHarvard,Boston,MA,USA. 4Department of Biostatistics andComputational Biology,Dana-Farber
Cancer Institute, Boston, MA, USA. 5Division of Hematology and Medical Oncology, Meyer Cancer Center, New York-Presbyterian Hospital, New York, NY,
USA. 6Amyloidosis Program, Division of Hematology, Brigham and Women’s Hospital and Dana Farber Cancer Institute, Boston,MA, USA. 7Cancer Center and
Department of Pathology, Massachusetts General Hospital, Boston, MA, USA. 8These authors contributed equally: Omar Nadeem, Michelle P. Aranha.
A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease
Davids M, et al.
Journal of Clinical Oncology
December 2024
Authors and Affiliates
Matthew S. Davids, M.D., M.M.Sc.1, Christine E. Ryan, M.D.1, Benjamin L. Lampson, M.D.,
Ph.D.1, Yue Ren, M.S.2, Svitlana Tyekucheva, Ph.D.2, Stacey M. Fernandes, B.S.1, Jennifer
L. Crombie, M.D.1, Austin I. Kim, M.D.1, Matthew Weinstock, M.D.3, Josie Montegaard,
N.P.1, Heather A. Walker, M.P.H.1, Claire Greenman, B.A.,1 Victoria Patterson, R.N.1, Caron
A. Jacobson, M.D., M.M.Sc.1, Ann S. LaCasce, M.D., M.M.Sc.1, Philippe Armand, M.D.,
Ph.D.1, David C. Fisher, M.D.1, Steve Lo, M.D.,4 Adam J. Olszewski, M.D.,5 Jon E. Arnason,
M.D.3, Inhye E. Ahn, M.D.1, Jennifer R. Brown, M.D., Ph.D.1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA
3Department of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA,
USA
4Stamford Hospital, Stamford, CT, USA
5Brown University Health, Providence, RI, USA
Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma
Vogl D, et al.
Blood
December 2024
Authors and Affiliates
Dan T. Vogl,1 Shebli Atrash,2 Sarah A. Holstein,3 Omar Nadeem,4 Don
Benson,5 Maria Chaudry,5 Noa Biran,6 Kaveri Suryanarayan,7 Cheryl Li,7 Yuyin Liu,7
Sabrina Collins,7 Xavier Parot,7 and Jonathan L. Kaufman8
Affiliations: 1 Abramson Cancer Center, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, PA, USA; 2 Levine Cancer Institute, Charlotte, NC, USA;
3University of Nebraska Medical Center, Omaha, NE, USA; 4 Dana-Farber Cancer
Institute, Boston, MA, USA; 5 Ohio State University Comprehensive Cancer Center,
Columbus, OH, USA; 6John Theurer Cancer Center, Hackensack, NJ, USA; 7 Takeda
Development Center Americas, Inc. (TDCA), Lexington, MA, USA; 812 Winship Cancer
13 Institute of Emory University, Atlanta, GA, USA
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
Roddie C, et al.
nejm
November 2024
Authors and Affiliates
Claire Roddie, M.D., Karamjeet S. Sandhu, M.D., Eleni Tholouli, M.D.,
Aaron C. Logan, M.D., Paul Shaughnessy, M.D., Pere Barba, M.D.,
Armin Ghobadi, M.D., Manuel Guerreiro, M.D., Deborah Yallop, M.D.,
Mehrdad Abedi, M.D., Jeremy M. Pantin, M.D., Jean A. Yared, M.D.,
Amer M. Beitinjaneh, M.D., Sridhar Chaganti, M.D., Katharine Hodby, M.D.,
Tobias Menne, M.D., Martha L. Arellano, M.D., Ram Malladi, M.D., Bijal D. Shah, M.D.,
Luke Mountjoy, M.D., Kristen M. O’Dwyer, M.D., Karl S. Peggs, M.D.,
Pierre Lao‑Sirieix, Ph.D., Yiyun Zhang, Ph.D., Wolfram Brugger, M.D.,
Edgar Braendle, M.D., Martin Pule, M.D., Michael R. Bishop, M.D.,
Daniel J. DeAngelo, M.D., Jae H. Park, M.D., and Elias Jabbour, M.D.
the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London
Hospitals NHS Foundation Trust (C.R.), King’s College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z.,
W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust,
Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation
Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) — all in the United Kingdom;
City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program,
University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) — all in California;
the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D.
Anderson Cancer Center, Houston (E.J.) — both in Texas; Hospital Universitari Vall d’Hebron–Universitat Autónoma de Barcelona,
Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) — both in Spain; Washington University School of
Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville
(J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.),
and Moffitt Cancer Center, Tampa (B.D.S.) — both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado
Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan
Kettering Cancer Center, New York (J.H.P.) — both in New York; the David and Etta Jonas Center for Cellular Therapy, University of
Chicago, Chicago (M.R.B.); and Dana–Farber Cancer Institute, Boston (D.J.D.).
MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma
Bhutani M, et al.
Blood Advances
November 2024
Authors and Affiliates
Manisha Bhutani,1,* Myra Robinson,2 David Foureau,3 Shebli Atrash,1 Barry Paul,1 Fei Guo 3,
Jason M Grayson 4, Anna Ivanina-Foureau, 3 Mauricio Pineda-Roman,1 Cindy Varga,1 Reed
Friend,1 Christopher J. Ferreri,1 Xhevahire Begic,5 Sarah Norek,5 Tiffany Drennan,6 Michelle B
Anderson,2 James T. Symanowski,2 Peter M. Voorhees,1,** and Saad Z. Usmani7,***
1Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer
Institute, Wake Forest University School of Medicine, Charlotte, NC, USA
2Department of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health,
Charlotte, NC, USA
3Immune Monitoring Core Laboratory, Atrium Health Levine Cancer Institute, Charlotte, NC,
USA
4Department of Microbiology and Immunology, Wake Forest School of Medicine, Winston-
Salem, NC, USA
5Atrium Health Wake Forest Baptist Comprehensive Cancer Center Data Coordinating Center,
Levine Cancer Institute, Charlotte, NC
6Clinical Trials Unit, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
7Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan
Kettering Cancer Center, New York, NY, USA
MRD-negative duration following latest line of therapy predicts long-term PFS in real-world multiple myeloma patients
Chen L, et al.
Blood Advances
November 2024
Authors and Affiliates
Lucia Y Chen1, Santiago Thibaud2, Saoirse Bodnar2, Ajai Chari3, Joshua Richter2, Hearn Jay Cho2, Larysa
J Sanchez2, Cesar Rodriguez2, Adriana C Rossi2, Shambavi Richard2, Samir Parekh2, Sundar Jagannath2*
1. Weatherall Institute of Molecular Medicine, Oxford University, UK
2. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
3. University of California, San Francisco, California, USA
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study
Al-Sawaf O, et al.
Blood
October 2024
Authors and Affiliates
Othman Al-Sawaf,1 Sandra Robrecht,1 Can Zhang,1 Stefano Olivieri,2 Yi Meng Chang,3 Anna Maria Fink,1 Eugen Tausch,4
Christof Schneider,4 Matthias Ritgen,5 Karl-Anton Kreuzer,1 Liliya Sivchev,6 Carsten Utoft Niemann,7 Anthony Schwarer,8 Javier Loscertales,9
Robert Weinkove,10,11 Dirk Strumberg,12 Allanah Kilfoyle,13 Beenish S. Manzoor,14 Dureshahwar Jawaid,14 Nnadozie Emechebe,14
Jacob Devine,15 Michelle Boyer,16 Eva D. Runkel,14 Barbara Eichhorst,1 Stephan Stilgenbauer,4 Yanwen Jiang,15 Michael Hallek,1 and
Kirsten Fischer1
1Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf,
German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany; 2F. Hoffmann-La Roche Ltd, Basel, Switzerland; 3F. Hoffmann-
La Roche Ltd, Mississauga, ON, Canada; 4Division of CLL, Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany; 5Universitätsklinikum
Schleswig Holstein, Kiel, Germany; 6Multiprofile Hospital for Active Treatment Pazardjik, Pazardzhik, Bulgaria; 7Rigshospitalet, Copenhagen, Denmark; 8Box Hill
Hospital, Box Hill, VIC, Australia; 9Hospital De La Princesa, Madrid, Spain; 10Te Rerenga Ora Wellington Blood and Cancer Centre, Te Whatu Ora Health New
Zealand Capital, Wellington, New Zealand; 11Cancer Immunotherapy Program, Malaghan Institute of Medical Research, Wellington, New Zealand; 12Evangelisches
Krankenhaus Herne, Herne, Germany; 13Palmerston North Hospital, Palmerston North, New Zealand; 14AbbVie Inc, Chicago, IL; 15Genentech Inc,
South San Francisco, CA; and 16F. Hoffmann-La Roche Ltd, Welwyn, United Kingdom
Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation
Kumar A, et al.
Blood
October 2024
Authors and Affiliates
Anita Kumar, MD1, Jacob Soumerai, MD2, Jeremy S. Abramson, MD2, Jeffrey A. Barnes, MD2,
PhD, Philip Caron, MD1, Shalini Chhabra, MD1, Maria Chabowska, BSc1, Ahmet Dogan, MD1,
PhD1, Lorenzo Falchi, MD1, Clare Grieve, MPH1, Julie E. Haydu, MD PhD2, Patrick Connor
Johnson, MD2, Ashlee Joseph BS1, Hailey E. Kelly2, Alyssa Labarre1, Jennifer Kimberly Lue,
MD1, Rosalba Martignetti2, Joanna Mi, NP1, Alison Moskowitz, MD1, Colette Owens, MD1,
Sean Plummer2, Madeline Puccio2, Gilles Salles, MD, PhD1, Venkatraman Seshan, PhD1,
Elizabeth Simkins2, Natalie Slupe1, Honglei Zhang, MD1, and Andrew D. Zelenetz, MD, PhD1
1. Memorial-Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
2. Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA, USA